Short Interest in Ritter Pharmaceuticals, Inc. (RTTR) Expands By 66.5%

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 1,216,646 shares, a growth of 66.5% from the October 31st total of 730,523 shares. Based on an average daily volume of 864,270 shares, the days-to-cover ratio is currently 1.4 days. Approximately 3.0% of the shares of the stock are sold short.

Ritter Pharmaceuticals (NASDAQ RTTR) opened at $0.32 on Monday. Ritter Pharmaceuticals has a 1 year low of $0.28 and a 1 year high of $3.75.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). research analysts forecast that Ritter Pharmaceuticals will post -0.66 EPS for the current year.

An institutional investor recently raised its position in Ritter Pharmaceuticals stock. KCG Holdings Inc. grew its position in shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 105,409 shares of the biotechnology company’s stock after purchasing an additional 76,046 shares during the quarter. KCG Holdings Inc. owned approximately 0.91% of Ritter Pharmaceuticals worth $150,000 as of its most recent SEC filing. Institutional investors and hedge funds own 33.35% of the company’s stock.

Several brokerages have recently commented on RTTR. Chardan Capital reduced their price objective on Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating on the stock in a research report on Tuesday, August 8th. Zacks Investment Research lowered Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, HC Wainwright reduced their price objective on Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating on the stock in a research report on Monday, October 23rd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $2.92.

TRADEMARK VIOLATION NOTICE: “Short Interest in Ritter Pharmaceuticals, Inc. (RTTR) Expands By 66.5%” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://weekherald.com/2017/12/04/short-interest-in-ritter-pharmaceuticals-inc-rttr-expands-by-66-5.html.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply